Eisai Co EBIT

The latest EBIT for ESALY is $-1.6B as of December 2022. That compares with $72B in the prior-year period — down 102.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Eisai Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, ESALY's EBIT moved from $72B to $-1.6B — a 102.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eisai Co's operating scale or balance-sheet position.

Against Healthcare companies, ESALY currently prints $-1.6B for EBIT, while the sector average sits near $110B. That is roughly 101.4% below the sector mean. Large gaps often invite a closer look at Eisai Co's growth, margins, and balance sheet.

A EBIT figure of $-1.6B for ESALY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ESALY's EBIT ($-1.6B), review year-over-year change from $72B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.